Trigeminal Neuralgia - Pipeline Review, H1 2019

Global Markets Direct’s, ‘Trigeminal Neuralgia - Pipeline Review, H1 2019’, provides an overview of the Trigeminal Neuralgia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Trigeminal Neuralgia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Trigeminal Neuralgia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Trigeminal Neuralgia

- The report reviews pipeline therapeutics for Trigeminal Neuralgia by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Trigeminal Neuralgia therapeutics and enlists all their major and minor projects

- The report assesses Trigeminal Neuralgia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Trigeminal Neuralgia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Trigeminal Neuralgia

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Trigeminal Neuralgia pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Allergan Plc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

InMed Pharmaceuticals Inc

Merz Pharma GmbH & Co KgaA

PixarBio Corp

Allergan Plc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

InMed Pharmaceuticals Inc

Merz Pharma GmbH & Co KgaA

PixarBio Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Trigeminal Neuralgia (Tic Douloureux) – Overview

Trigeminal Neuralgia (Tic Douloureux) – Therapeutics ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Trigeminal Neuralgia (Tic Douloureux) – Overview

Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Trigeminal Neuralgia (Tic Douloureux) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Trigeminal Neuralgia (Tic Douloureux) – Companies Involved in Therapeutics Development

Allergan Plc

Biogen Inc

Biohaven Pharmaceutical Holding Company Ltd

InMed Pharmaceuticals Inc

Merz Pharma GmbH & Co KgaA

PixarBio Corp

Trigeminal Neuralgia (Tic Douloureux) – Drug Profiles

carbamazepine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GTX-201 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

incobotulinumtoxin A – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INM-405 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OLP-1002 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rimegepant – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Block TRPV4 and TRPA1 for Pancreatitis and Trigeminal Neuralgia – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vixotrigine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects

Trigeminal Neuralgia (Tic Douloureux) – Product Development Milestones

Featured News & Press Releases

Feb 27, 2018: PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat Trigeminal Neuralgia and Post-Surgical Pain

Sep 15, 2016: PixarBio CEO Frank Reynolds to Present NeuroRelease a Non-Addictive Morphine Replacement at the 2016 Aegis Capital Growth Conference in Las Vegas, NV on September 21, 2016

Jun 27, 2016: PixarBio Promotes David Kaplan to Chief Commercial Officer, as NeuroRelease a Morphine Strength Non Addictive Pain Treatment Remains on Track for 2018 Launch

Mar 30, 2016: PixarBio, the Developers of NeuroRelease A Revolutionary Morphine Strength, Non-Addictive Pain Treatment Appoints Glenn Reiser Vice President of External Affairs

Mar 03, 2016: PixarBio's Dr. Taunia Markvicka and Glenn Reiser to Discuss Breakthrough Data on Morphine Strength Non-Addictive Pain Treatment NeuroRelease at the 2016 Congress of Neurological Surgeons Spine Summit held in Orlando, FL March 17-18, 2016

Nov 30, 2015: PixarBio's Glenn Reiser to Present Data on NeuroRelease, a Breakthrough Non-opiate and Non-addictive Pain Platform, at the 2015 Life Sciences Summit in New York, NY

Oct 26, 2015: PixarBio Announces USFDA OPD Submission of NeuroRelease TN for Orphan Drug Designation for Trigeminal Neuralgia

Sep 23, 2014: Convergence Pharmaceuticals' Novel Nav1.7 Selective Sodium Channel Blocker CNV1014802 Demonstrates Proof of Concept in Second Neuropathic Pain Study in Lumbosacral Radiculopathy

Jun 16, 2014: Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy and Safety in Ground-breaking Phase II Trigeminal Neuralgia Study

Jul 30, 2013: Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802

Apr 23, 2013: Convergence Pharma Announces Successful Interim Data From Phase II Trigeminal Neuralgia Study

Mar 27, 2013: Convergence Pharma Reports Positive Interim Data From Phase II Trigeminal Neuralgia Study Of CNV-1014802

Mar 19, 2012: Convergence Initiates Phase II Study For CNV1014802 For Trigeminal Neuralgia

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Tables

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Allergan Plc, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Biogen Inc, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by InMed Pharmaceuticals Inc, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by Merz Pharma GmbH & Co KgaA, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Pipeline by PixarBio Corp, H1 2019

Trigeminal Neuralgia (Tic Douloureux) – Dormant Projects, H1 2019

List of Figures

List of Figures

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2019

Number of Products under Development by Companies, H1 2019

Number ...

List of Figures

Number of Products under Development for Trigeminal Neuralgia (Tic Douloureux), H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Top 10 Targets, H1 2019

Number of Products by Stage and Top 10 Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Top 10 Routes of Administration, H1 2019

Number of Products by Stage and Top 10 Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports